Archive


Category: ~$1.45B

  • Sanofi to Acquire Kymab for ~$1.45B

    Shots: Sanofi to acquire Kymab for $1.1B up front and ~$350M following the achievement of certain milestones. The transaction is expected to be completed in H1’21 The acquisition will add KY1005 to Sanofi’s pipeline and will expedite its presence in the field of immunology Sanofi will get the global rights of KY1005 which is a […]